Substituted 4-pyrimidone compounds, compositions and methods of use
AssigneeSmith Kline & French Laboratories Limited
InventorsThomas H. Brown, Graham J. Durant, John C. Emmett, Charon R. Ganellin
Life of this patent
Estimating the term…
Abstract
The compounds are substituted isocytosines which are histamine H.sub.2 -antagonists. Two specific compounds of the present invention are 2-[2-(5-methyl-4-imidazolylmethylthio)ethylamino]-5-(3-methoxybenzyl)-4-py rimidone and 2-[2-(5-methyl-4-imidazolylmethylthio)ethylamino]-5-benzyloxy-4-pyrimidone .
Claims21
A compound of the formula:
- ##STR9## wherein Het' is a 2- or 4-imidazolyl ring optionally monosubstituted by lower alkyl, halogen, trifluoromethyl or hydroxymethyl, a 2-pyridyl ring optionally monosubstituted by lower alkyl, lower alkoxy, halogen, amino or hydroxy, a 2-pyridyl ring which is disubstituted by lower alkoxy groups, or which has a phenyl, carbocyclic or cyclic ether ring having two oxygen atoms fused to it, a 2-thiazolyl ring, a 3-isothiazolyl ring optionally monosubstituted by chlorine or bromine, a 3-(1,2,5)-thiadiazolyl ring optionally monosubstituted by chlorine or bromine, or a 2-(5-amino-1,3,4-thiadiazolyl)ring;
- Z is sulphur or a methylene group;
- X is oxygen or sulphur;
- W is methylene, oxygen or sulphur;
- m and n are such that their sum is from 1 to 4 when W is oxygen or sulphur, or from 0 to 4 when W is methylene;
- A is a 2,3-dihydro-1,4-benzodioxinyl or a 1,3-benzodioxolyl ring, a phenyl ring substituted with one or more phenylloweralkoxy (said phenyl being optionally monosubstituted by chloro or methoxy), loweralkoxyloweralkoxy, trifluoromethyl, di(loweralkyl)amino, phenoxy, halophenoxy, lower alkoxyphenoxy, phenyl, halophenyl or lower alkoxyphenyl groups and when W is not a methylene group, A may also be phenyl;
- and Y.sup.3 is hydrogen or lower alkyl;
- or a pharmaceutically acceptable acid addition salt thereof.
A method of blocking histamine H.sub.2 -receptors of claim 29 which comprises administering to an animal in need thereof an effective amount of 2-[2-(5-methyl-4-imidazolylmethylthio)ethylamino]-5-(5-(1,3-benzodioxol yl)methyl)-4-pyrimidone or a pharmaceutically acceptable salt thereof.
A pharmaceutical composition to block histamine H.sub.2 -receptors of claim 28 comprising, in an effective amount to block said receptors 2-[2-(5-methyl-4-imidazolylmethylthio)ethylamino]-5-(6-(2,3-dihydro-1,4-be nzodioxinyl)methyl]-4-pyrimidone or a pharmaceutically acceptable acceptable salt thereof in combination with a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.